Organic compounds -- part of the class 532-570 series – Organic compounds – Carboxylic acid esters
Reexamination Certificate
2007-12-04
2007-12-04
Puttlitz, Karl (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carboxylic acid esters
C562S469000
Reexamination Certificate
active
10830480
ABSTRACT:
A compound represented by the following formula (1), a pharmaceutically acceptable salt thereof or an optically active form thereof:wherein each symbol is as defined in the specification. A compound having a calcium-sensing receptor antagonistic action, a pharmaceutical composition comprising the compound, particularly a calcium receptor antagonist and a therapeutic drug for osteoporosis are provided.
REFERENCES:
patent: 6022894 (2000-02-01), Del Mar et al.
patent: 6291459 (2001-09-01), Bhatnagar et al.
patent: 6294531 (2001-09-01), Barmore et al.
patent: 6334338 (2002-01-01), Mandich et al.
patent: 6395919 (2002-05-01), Bhatnagar et al.
patent: 6417215 (2002-07-01), Largo
patent: 6521667 (2003-02-01), Del Mar et al.
patent: 6916956 (2005-07-01), Shinagawa et al.
patent: 2002/0052509 (2002-05-01), Bhatnagar et al.
patent: 2002/0099220 (2002-07-01), Del Mar et al.
patent: 2003/0018203 (2003-01-01), Lago et al.
patent: 2003/0212110 (2003-11-01), Bhatnagar et al.
patent: 2004/0006130 (2004-01-01), Shinagawa et al.
patent: 2004/0009980 (2004-01-01), Bhatnagar et al.
patent: 2004/0014723 (2004-01-01), Bhatnagar et al.
patent: 2004/0180912 (2004-09-01), Beerti et al.
patent: 2004/0192741 (2004-09-01), Lago et al.
patent: 2001-501584 (2001-02-01), None
patent: 2001-523223 (2001-11-01), None
patent: 2002-510636 (2002-04-01), None
patent: 2002-510671 (2002-04-01), None
patent: 2002-522499 (2002-07-01), None
patent: 2002-522532 (2002-07-01), None
patent: 2002-536330 (2002-10-01), None
patent: WO 97/37967 (1997-10-01), None
patent: WO 98/45255 (1998-10-01), None
patent: WO 99/51241 (1999-10-01), None
patent: WO 99/51569 (1999-10-01), None
patent: WO 00/09132 (2000-02-01), None
patent: WO 00/09491 (2000-02-01), None
patent: WO 00/45816 (2000-08-01), None
patent: WO 01/53254 (2001-07-01), None
patent: WO 02/07673 (2002-01-01), None
patent: WO 02/14259 (2002-02-01), None
patent: WO 02/34204 (2002-05-01), None
patent: WO 02/38106 (2002-05-01), None
patent: WO 02/102782 (2002-12-01), None
patent: WO 2004/106280 (2004-12-01), None
Brown, E.M., “Homeostatic Mechanisms Regulating Extracellular and Intracellular Calcium Metabolism, The Parathyroid,” p. 19, (1994), Raven press, New York.
Tam et al., “Parathyroid Hormone Stimulates the Bone Apposition Rate Independently of its Resorptive Action: Differential Effects of Intermittent and Continuous Administration,” Endocrinology, The Endocrine Society, vol. 110, No. 2, pp. 506-512, (1982).
Uzawa et al., “Comparison of the Effect of Intermittent and Continuous Administration of Human Parathyroid Hormone (1-34) on Rat Bone,” Bone, Elsevier, vol. 16, No. 4, pp. 477-484, (1995).
Scutt et al., “Time-Dependent Effects of Parathyroid Hormone and Prostaglandin E2on DNA Synthesis by Periosteal Cells From Embryonic Chick Calvaria,” Calcified Tissue Int., vol. 55, pp. 208-215 (1994).
Wronski et al., “Parathyroid Hormone is More Effective Than Estrogen or Bisphosphonates for Restoration of Lost Bone Mass in Ovariectomized Rats,” Endocrinology, The Endocrine Society, vol. 132, No. 2, pp. 823-831 (1993).
Wronski et al., “Anabolic Effects of Parathyroid Hormone on Cortical Bone in Ovariectomized Rats,” Bone, vol. 15, No. 1, pp. 51-58, (1994).
Mosekilde et al., “The Anabolic Effects of Human Parathyroid Hormone (hPTH) on Rat Vertebral Body Mass Are Also Reflected in the Quality of Bone, Assessed by Biomechanical Testing: A Comparison Study Between hPTH-(1-34) and hPTH-(1-84),” Endocrinology, The Endocrine Society, vol. 129, No. 1, pp. 421-428 (1991).
Ejersted et al., “Human Parathyroid Hormone (1-34) and (1-84) Increase The Mechanical Strength and Thickness of Cortical Bone in Rats,” Journal of Bone and Mineral Research, vol. 8, No. 9, pp. 1097-1101, (1993).
Brown et al., “Cloning and Characterization of an Extracellular Ca2+-Sensing Receptor From Bovine Parathyroid,” Letters to Nature, vol. 366, No. 9, pp. 575-580, (1993).
Gowen et al., “Antagonizing the Parathyroid Calcium Receptor Stimulates Parathyroid Hormone Secretion and Bone Formation in Osteopenic Rats,” The Journal of Clinical Investigation, vol. 105, No. 11, pp. 1595-1604 (2000).
Fukuda Kenji
Ikenogami Taku
Inoue Teruhiko
Kiguchi Toshihiro
Nakagawa Takashi
Japan Tobacco Inc.
Puttlitz Karl
LandOfFree
CaSR antagonist does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CaSR antagonist, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CaSR antagonist will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3895899